PoliticalRepoPoliticalRepo

European Union · Record · TJ

CELEX 62024TJ0012

Judgment of the General Court (Eighth Chamber) of 2 September 2026.#Ferring Pharmaceuticals A/S v European Commission.#Medicinal products for human use – Generic medicinal products – Marketing authorisation for the medicinal product for human use Degarelix Accord – degarelix acetate – Lack of bioequivalence study with the reference medicinal product – Article 10(1) and (2) of Directive 2001/83/EC – Manifest error of assessment – Principle of good administration.#Case T-12/24.

decidedEuropean Union· Court of Justice of the European Union· EN

Introduced

2 September 2026

Last action

2 September 2026 · Decided

Status

decided

Sponsors

Subjects

Discovery layer

Source updated

2 September 2026

Official titles

Authentic titles published by the source. The stored canonical title is not replaced.

1 official language
  • French

    Arrêt du Tribunal (huitième chambre) du 2 septembre 2026.#Ferring Pharmaceuticals A/S contre Commission européenne.#Médicaments à usage humain – Médicaments génériques – Autorisation de mise sur le marché du médicament à usage humain Degarelix Accord – acétate de dégarélix – Absence d’étude de bioéquivalence avec le médicament de référence – Article 10, paragraphes 1 et 2, de la directive 2001/83/CE – Erreur manifeste d’appréciation – Principe de bonne administration.#Affaire T-12/24.

Records

Official record CELEX 62024TJ0012 from European Union at Court of Justice of the European Union. Dated 2 September 2026. Status: decided.

Timeline

  1. 2 September 2026

    Decided

    Source: work_date_document

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

Judgment of the General Court (Eighth Chamber) of 2 September 2026.#Ferring Pharmaceuticals A/S v European Commission.#Medicinal products for human use – Generic medicinal products – Marketing authorisation for the medicinal product for human use Degarelix Accord – degarelix acetate – Lack of bioequivalence study with the reference medicinal product – Article 10(1) and (2) of Directive 2001/83/EC – Manifest error of assessment – Principle of good administration.#Case T-12/24.

View fileDownload file

  • Judgment of the General Court (Eighth Chamber) of 2 September 2026.#Ferring Pharmaceuticals A/S v European Commission.#Medicinal products for human use – Generic medicinal products – Marketing authorisation for the medicinal product for human use Degarelix Accord – degarelix acetate – Lack of bioequivalence study with the reference medicinal product – Article 10(1) and (2) of Directive 2001/83/EC – Manifest error of assessment – Principle of good administration.#Case T-12/24.

    judgment · EN · 2 September 2026

    ViewDownloadOpen at official source

  • Arrêt du Tribunal (huitième chambre) du 2 septembre 2026.#Ferring Pharmaceuticals A/S contre Commission européenne.#Médicaments à usage humain – Médicaments génériques – Autorisation de mise sur le marché du médicament à usage humain Degarelix Accord – acétate de dégarélix – Absence d’étude de bioéquivalence avec le médicament de référence – Article 10, paragraphes 1 et 2, de la directive 2001/83/CE – Erreur manifeste d’appréciation – Principe de bonne administration.#Affaire T-12/24.

    judgment · FR · 2 September 2026

    ViewDownloadOpen at official source

Sponsors

  • · GCEU · General Court

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.